Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ML-007C-MA in Schizophrenia
NCT07038876Phase 2Completed
- Sponsor
- MapLight Therapeutics
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ML-007/PAC in schizophrenia, sponsored by MapLight Therapeutics. Started Jun 2025; status: completed.
02
Drugs
ML-007/PAC
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07038876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038876.